Any Sales Representative Care To Share Insight About Afrezza Relaunch

Discussion in 'Amplity' started by anonymous, Aug 10, 2016 at 8:09 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Sales Reps have been selling Afrezza for about 3 weeks and it would be appreciated if someone can share how they are doing and what kind of interest is being seen in the marketplace for Afrezza. Thank you
     

  2. anonymous

    anonymous Guest

    no one is going to buy that crap drug when the delivery mechanism hasn't been tested.
     
  3. anonymous

    anonymous Guest

    Apparently the same as before. Next to no interest. Too complicated, too much pre-work testing, too limited a patient base (non-smokers). Meanwhile needles are intimidating at first but after a week people are fine with it. Sucks out here.
     
  4. anonymous

    anonymous Guest

    Symphony data week ending 8/5/16:

    NRx = 117
    TRx = 276

    enuf said - 276 for a week. good job
     
  5. anonymous

    anonymous Guest

    any sales representative care to share your experience selling Afrezza
     
  6. anonymous

    anonymous Guest

    My experience? Get me outta here. Please!!
     
  7. anonymous

    anonymous Guest

    I almost accepted a position on this project. What is it that makes you wanna get out?
     
  8. anonymous

    anonymous Guest

    I was passed over for this sales job by Touchpoint Publicis in favor of their local loser rep that had just gotten laid off by tumultuous AstraZeneca. Since then MannKind stock has gone from $1.02 to 59 cents. Look out belo-o-o-o-o-ow !! Idiot MandKind CMO Costagna's stock options are way underwater.
    Ha ha ha ha ha ha ha ha ha ha ha ha ha ha ha ha ha ha ha !